[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643837":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":50,"collaborators":52,"id":55,"slug":20,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Florida","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single arm study of subjects with HFpEF","EXPERIMENTAL","Subjects with HFpEF undergo a baseline gadolinium based cardiac MRI and the same day they undergo an iron infusion. Three days later they return for a follow-up cardiac MRI and the iron that has been administered 72 hours ago serves as the contrast media",[13],"Drug: Ferumoxytol infusion",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Ferumoxytol infusion","Ferumoxytol infusion followed by cardiac MRI",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Ellen C Keeley, MD, MS","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","800-265-0820","ellen.keeley@medicine.ufl.edu",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Vanessa H Scheuble","800-555-0820","Vanessa.scheuble@medicine.ufl.edu",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Gainesville","Florida","32608","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-82.32483,29.65163,{"lat":46,"lon":45},[49],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"type":51,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[53],{"name":54,"class":6},"American Heart Association","100643837",false,"NCT07634640","Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction","Omega-3 Fatty Acids and Myocardial Inflammation in HFpEF: Preliminary Data and Next Steps","Inclusion Criteria:\n\n* HFpEF\n\nExclusion Criteria:\n\n* Renal insufficiency","ALL","18 Years","85 Years",{"count":65,"type":66},70,"ESTIMATED","INTERVENTIONAL",[69],"EARLY_PHASE1","Subjects undergo a gadolinium-based CMR followed by an iron infusion and then a repeat CMR in 72 hours",[72],"Heart Failure With Preserved Ejection Fraction (HFPEF)",[74],"heart failure with preserved ejection fraction","2026-06-04",{"date":77,"type":78},"2026-06-09","ACTUAL",{"date":80,"type":78},"2023-11-03",{"date":82,"type":66},"2027-05-31",{"name":5,"class":6},1]